PHARNEXT: Pharnext unveils the latest progress of the PREMIER trial, pivotal Phase III clinical trial of PXT3003 in Charcot-Marie-Tooth disease type 1A

PARIS, France, February 2nd, 2023, 08:30 am CET - Pharnext SA (FR001400BV89 - ALPHA) (the "Company"), an advanced late-clinical stage biopharmaceutical company developing novel therapeutics for neurodegenerative

Related Keywords

United States ,Paris ,France General ,France ,Canada ,Israel ,Schwann ,Baden Wüberg ,Germany ,Deborah Schwarz ,Mary Jane Elliott ,Fabreguettes Leib ,Alexandra Harrison ,Sukaina Virji ,Schwierige Zeiten ,Financial Press Relations ,Relations International ,Euronext Growth Stock Exchange ,Clinical Development Program ,Consilium Strategic Communications ,Overall Neuropathy Limitations Scale ,Open Label Extension ,Chief Medical Officer ,Charcot Marie Tooth Disease Type ,Meter Walk Test ,Quantified Muscular Testing ,Patient Global Impression ,Charcot Marie Tooth Neuropathy Score ,Announces First Patient Enrolled ,Pivotal Phase ,Development Program ,Announces On Schedule Completion ,Patient Enrollment ,Pharnext ,Nveils ,Latest ,Progress ,Premier ,Trial ,Pivotal ,Hase ,Linical ,Xt3003 ,Charcot ,Marie ,Tooth ,Disease ,Type ,